Company
The core of the industry is providing competitive research technology proven by the optimized radiochemical yield.
The Top
Top sales in every product line in Korea
The First
The first Korean company to export
The Largest
The largest product portfolio and pipeline in the country
The Only
The only developer of GEP-NET Therapeutic Radiopharmaceutical in Korea
Stable
Stable and largest
RP-manufacturing
network in Korea
Representative
Representative Radiopharmaceutical company in Korea
Development of new drugs with competitive technology proven by the optimized
Radiochemical yield, achieving successful commercialization
Creating virtuous cycle
Intellectual Properties of DCB
Patent/Trademark | Patents | Trademark | Remarks | ||||
---|---|---|---|---|---|---|---|
23/1 | Domestic | International | Domestic | PCT Application : 5 |
|||
Pending | Registered | Pending | Registered | Pending | Registered | ||
Total | - | 23 | 19 | 10 | - | 1 |
Market Share (%)
First-mover and No.1 in market share in each product
FDG
0 %FP-CIT
0 %Neuraceq
0 %(Source: MFDS “Integrated Information System”, 2019)
The passion to challenge a new market
where everything is a beginning!
With our experience in Korea,
we will pursue the passion in Southeast Asia